Kailera Therapeutics, Inc. - 10-Q Filing
Kailera Therapeutics reports third quarter 2026 financial results including segment performance for KAI-4729, Safiglipron, and Ribupatide.
Tickers: $KLRA
More Regulatory news
- UNITED BANCORP INC /OH/ - 10-Q Filing
- PATRIOT GOLD CORP - 10-Q Filing
- First Digital Acquisition Corp Ltd. - 8-K Filing
- GROOVE BOTANICALS INC. - 10-Q Filing
- Johnson Controls International plc - 10-K Filing
- OLD NATIONAL BANCORP /IN/ - 8-K Filing
- AMTECH SYSTEMS INC - 8-K Filing
- REGIONAL HEALTH PROPERTIES, INC - 8-K Filing
- Bitwise Avalanche ETF - 8-K Filing
- MiNK Therapeutics, Inc. - 10-Q Filing